TACE with QS-GMP shows promise for canine lower urinary tract carcinomas
Transarterial chemoembolization using quick-soluble gelatin microparticles resulted in a median tumor volume reduction of 76.41% in dogs with lower urinary tract carcinomas.
Phase III
Oncology / Veterinary
Status
Active
Sponsor
veterinary pharmaceutical companies
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The promising results of TACE using QS-GMP for treating canine lower urinary tract carcinomas could lead to significant advancements in veterinary oncology. This may prompt pharmaceutical companies to invest in further research and development of similar agents, potentially reshaping treatment standards in this niche market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for further studies on QS-GMP in larger cohorts and any developments in veterinary oncology treatment guidelines.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.